Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. [electronic resource]
Producer: 20150701Description: 502-9 p. digitalISSN:- 1873-7560
- Aged
- Antineoplastic Agents -- therapeutic use
- Axitinib
- Bisphosphonate-Associated Osteonecrosis of the Jaw -- etiology
- Bone Density Conservation Agents -- adverse effects
- Bone Neoplasms -- drug therapy
- Carcinoma, Renal Cell -- drug therapy
- Diphosphonates -- adverse effects
- Disease-Free Survival
- Female
- Humans
- Hypocalcemia -- chemically induced
- Imidazoles -- therapeutic use
- Indazoles -- therapeutic use
- Indoles -- therapeutic use
- Interferon-alpha -- therapeutic use
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- analogs & derivatives
- Pamidronate
- Phenylurea Compounds -- therapeutic use
- Prognosis
- Pyrroles -- therapeutic use
- Renal Insufficiency -- chemically induced
- Retrospective Studies
- Sirolimus -- analogs & derivatives
- Sorafenib
- Sunitinib
- Survival Rate
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.